Mounjaro vs Zepbound
Mounjaro vs Zepbound: both brands hold the same medicine, tirzepatide, from the same maker, Eli Lilly.
Paste this code into your page. It shows the GLP-1 comparison chart with one plain credit link.
Learn
More about this page
Tirzepatide acts on two hormone receptors, GIP and GLP-1. GLP-1 is a hormone from the gut that helps the body manage blood sugar and eating. The two brands have separate FDA labels with different approved uses. Both labels were updated in late August 2026.
Source: Drucker DJ, Cell Metabolism 2018, PMID 29617641.
The two labels side by side
| Label fact | Mounjaro | Zepbound |
|---|---|---|
| Medicine (molecule) | tirzepatide | tirzepatide |
| Type | GIP and GLP-1MOUNJARO® is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist | GIP and GLP-1ZEPBOUND is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist |
| Maker on the label | Eli Lilly and Company | Eli Lilly and Company |
| Taken as | Injection: pen or vial pre-filled single-dose pens, single-dose vials, multi-dose vials, or single-patient-use KwikPens | Injection: pen or vial pre-filled single-dose pens, single-dose vials, multi-dose vials, or single-patient-use KwikPens |
| How often, per label | Once weekly Administer MOUNJARO once weekly, any time of day, with or without meals. | Once weekly Administer ZEPBOUND once weekly at any time of day, with or without meals. |
| Approved uses, per label |
|
|
| Boxed warning | Yes WARNING: RISK OF THYROID C-CELL TUMORS | Yes WARNING: RISK OF THYROID C-CELL TUMORS |
| Label read | Mounjaro label, version 40, effective August 27, 2026 | Zepbound label, version 40, effective August 28, 2026 |
| FDA approval record | NDA215866, first approved May 13, 2022 | NDA217806, first approved November 8, 2023 |
Each cell is the label's own wording, and each label link opens the exact DailyMed version we read.
Where the two labels differ
- Approved uses. The Mounjaro label is about type 2 diabetes. It lists blood sugar control and, for adults with type 2 diabetes at high risk, a lower risk of major cardiovascular events. The label defines those as cardiovascular death, a heart attack that is not fatal, or a stroke that is not fatal. The Zepbound label lists excess body weight and obstructive sleep apnea in adults with obesity.
- Ages. The Mounjaro label includes children 10 years and older for blood sugar control. The Zepbound label lists adults.
- FDA approval records. Mounjaro was first approved in 2022 and Zepbound in 2023, under separate applications.
Using tirzepatide products together
The Zepbound label has a limitation of use about other tirzepatide products and GLP-1 medicines. The label's exact words are below.
| Zepbound label, section 1, Limitations of Use | Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended. |
|---|
More side by side pages
For the two semaglutide brands, see Ozempic vs Wegovy. For tirzepatide next to semaglutide, see tirzepatide vs semaglutide. The how do GLP-1 drugs work page explains how each one acts. To compare any other pair, use the GLP-1 comparison chart.
Questions
Is Mounjaro the same as Zepbound?
Mounjaro and Zepbound hold the same medicine, tirzepatide, from the same maker. But each has its own FDA label, with its own approved uses.
What is the difference between Mounjaro and Zepbound?
The labels differ in approved uses and ages. Mounjaro's label is for type 2 diabetes, including children 10 and older for blood sugar. Zepbound's label is for excess body weight and sleep apnea in adults.
Is Mounjaro a GLP-1?
Mounjaro acts on GLP-1 and on a second hormone receptor. The Mounjaro label calls tirzepatide a GIP receptor and GLP-1 receptor agonist.
Is Zepbound a GLP-1?
The Zepbound label uses the same words as Mounjaro: a GIP receptor and GLP-1 receptor agonist. So it acts on GLP-1 and on GIP.
Sources
4 sources with read dates
- Mounjaro label on DailyMed, Eli Lilly, version 40 of 2026-08-27, read 2026-10-06
- Zepbound label on DailyMed, Eli Lilly, version 40 of 2026-08-28, read 2026-10-06
- Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1, Drucker DJ, Cell Metabolism 2018, PMID 29617641, abstract read on PubMed 2026-10-06
- Drugs@FDA application records for NDA 215866 and 217806, US Food and Drug Administration, via the openFDA drugsfda API, read 2026-10-06